Ignite SD
0
Login
Register
Viewing Study NCT00261092
Home
Search
Stocks
Certify Doc
Genes
Clinical Trials
CompTox
DrugMatrix
Open Targets
Products
Support
Bugs
eRecord
Main Search
All Studies
All Organizations
Report Bug
View Study With Definitions
Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00261092
Status:
COMPLETED
Last Update Posted:
2008-04-15
First Post:
2005-12-01
Brief Title:
GEMOX Oxaliplatin in Pancreatic Cancer
Sponsor:
Sanofi
Organization:
Sanofi
Overview
Dates
Organization
Conditions
Design
Enrollment
Locations
Outcomes
Study Overview
Official Title:
Phase II Multicenter Open Label Study of Oxaliplatin Combined With GemcitabineGEMOX in Advanced and Metastatic Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary objective
To evaluate overall response rate based on RECIST criterion
Secondary objective
To evaluate time to progression clinical benefit quality of life and safety
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None